• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Effects of Zhenggan Huayu decoction combined with entecavir on gut microbiota in patients with chronic hepatitis B fibrosis.正肝化瘀汤联合恩替卡韦对慢性乙型肝炎肝纤维化患者肠道菌群的影响。
J Tradit Chin Med. 2023 Jun;43(3):559-567. doi: 10.19852/j.cnki.jtcm.20230208.002.
2
Alterations in gut microbiome and metabolomics in chronic hepatitis B infection-associated liver disease and their impact on peripheral immune response.慢性乙型肝炎感染相关肝病中肠道微生物组和代谢组学的改变及其对外周免疫反应的影响。
Gut Microbes. 2023 Jan-Dec;15(1):2155018. doi: 10.1080/19490976.2022.2155018.
3
Changes in APRI and FIB-4 in HBeAg-negative treatment-naive chronic hepatitis B patients with significant liver histological lesions receiving 5-year entecavir therapy.恩替卡韦治疗 5 年后有明显肝脏组织学病变的 HBeAg 阴性初治慢性乙型肝炎患者的 APRI 和 FIB-4 的变化。
Clin Exp Med. 2019 Aug;19(3):309-320. doi: 10.1007/s10238-019-00560-z. Epub 2019 May 20.
4
Histological outcome for chronic hepatitis B patients treated with entecavir vs lamivudine-based therapy.恩替卡韦与基于拉米夫定的疗法治疗慢性乙型肝炎患者的组织学结果。
World J Gastroenterol. 2015 Aug 28;21(32):9598-606. doi: 10.3748/wjg.v21.i32.9598.
5
Entecavir therapy reverses gut microbiota dysbiosis induced by hepatitis B virus infection in a mouse model.恩替卡韦治疗可逆转乙型肝炎病毒感染小鼠模型中的肠道微生物失调。
Int J Antimicrob Agents. 2020 Jul;56(1):106000. doi: 10.1016/j.ijantimicag.2020.106000. Epub 2020 Apr 29.
6
Chinese herbal formula ruangan granule enhances the efficacy of entecavir to reverse advanced liver fibrosis/early cirrhosis in patients with chronic HBV infection: A multicenter, randomized clinical trial.中药复方软肝颗粒增强恩替卡韦逆转慢性HBV感染患者晚期肝纤维化/早期肝硬化的疗效:一项多中心随机临床试验。
Pharmacol Res. 2023 Apr;190:106737. doi: 10.1016/j.phrs.2023.106737. Epub 2023 Mar 20.
7
Evaluation of the efficacy of Biejia decoction pill combined with entecavir in the treatment of hepatitis B liver fibrosis/cirrhosis by VCTE.超声瞬时弹性成像技术评价鳖甲煎丸联合恩替卡韦治疗乙肝肝纤维化/肝硬化的疗效。
Sci Rep. 2023 Nov 10;13(1):19616. doi: 10.1038/s41598-023-46459-4.
8
[Predictive value of liver pathologic changes in determining the effectiveness of entecavir treatment for chronic hepatitis B-An analysis of 1 366 cases].[肝脏病理改变对判断恩替卡韦治疗慢性乙型肝炎疗效的预测价值——1366例分析]
Zhonghua Yi Xue Za Zhi. 2017 Apr 18;97(15):1160-1164. doi: 10.3760/cma.j.issn.0376-2491.2017.15.010.
9
Impact of Fuzheng Huayu tablet on antiviral effect of entecavir in patients with hepatitis B cirrhosis.扶正化瘀片对乙型肝炎肝硬化患者恩替卡韦抗病毒疗效的影响。
Hepatobiliary Pancreat Dis Int. 2022 Oct;21(5):479-484. doi: 10.1016/j.hbpd.2022.03.007. Epub 2022 Mar 10.
10
Entecavir plus Biejia-Ruangan compound reduces the risk of hepatocellular carcinoma in Chinese patients with chronic hepatitis B.恩替卡韦联合鳖甲软肝片降低中国慢性乙型肝炎患者肝细胞癌的发生风险。
J Hepatol. 2022 Dec;77(6):1515-1524. doi: 10.1016/j.jhep.2022.07.018. Epub 2022 Aug 18.

引用本文的文献

1
Effects of Bushen Huayu Decoction combined with entecavir on liver function and hepatic fibrosis in patients with compensated cirrhosis.补肾化瘀汤联合恩替卡韦对代偿期肝硬化患者肝功能及肝纤维化的影响
Am J Transl Res. 2024 Aug 15;16(8):4163-4173. doi: 10.62347/QDXJ3369. eCollection 2024.
2
Potential mechanisms of traditional Chinese medicine in the treatment of liver cirrhosis: a focus on gut microbiota.中医治疗肝硬化的潜在机制:聚焦肠道微生物群
Front Microbiol. 2024 Aug 21;15:1407991. doi: 10.3389/fmicb.2024.1407991. eCollection 2024.

本文引用的文献

1
Ambient temperature structures the gut microbiota of zebrafish to impact the response to radioactive pollution.环境温度构建斑马鱼肠道微生物组,影响其对放射性污染的响应。
Environ Pollut. 2022 Jan 15;293:118539. doi: 10.1016/j.envpol.2021.118539. Epub 2021 Nov 16.
2
Clinical efficacy and safety of traditional Chinese medicine Xiao Yao San in insomnia combined with anxiety.中药逍遥散治疗失眠伴焦虑的临床疗效及安全性。
Medicine (Baltimore). 2021 Oct 29;100(43):e27608. doi: 10.1097/MD.0000000000027608.
3
Methodological challenges of performing meta-analyses to compare the risk of hepatocellular carcinoma between chronic hepatitis B treatments.进行荟萃分析以比较慢性乙型肝炎治疗方案的肝细胞癌风险时所面临的方法学挑战。
J Hepatol. 2022 Jan;76(1):186-194. doi: 10.1016/j.jhep.2021.09.017. Epub 2021 Sep 27.
4
Examining the gut-liver axis in liver cancer using organoid models.使用类器官模型研究肝癌中的肠-肝轴。
Cancer Lett. 2021 Jul 10;510:48-58. doi: 10.1016/j.canlet.2021.04.008. Epub 2021 Apr 20.
5
Gut Microbiota in Intestinal and Liver Disease.肠道微生物群与肠道和肝脏疾病
Annu Rev Pathol. 2021 Jan 24;16:251-275. doi: 10.1146/annurev-pathol-030320-095722. Epub 2020 Nov 24.
6
Entecavir combining Chinese herbal medicine for HBeAg-positive chronic hepatitis B patients: a randomized, controlled trial.恩替卡韦联合中草药治疗 HBeAg 阳性慢性乙型肝炎患者的随机对照试验。
Hepatol Int. 2020 Dec;14(6):985-996. doi: 10.1007/s12072-020-10097-z. Epub 2020 Oct 30.
7
Clinical Efficacy and Safety of Eight Traditional Chinese Medicine Combined with Entecavir in the Treatment of Chronic Hepatitis B Liver Fibrosis in Adults: A Network Meta-Analysis.八种中药联合恩替卡韦治疗成人慢性乙型肝炎肝纤维化的临床疗效与安全性:一项网状Meta分析
Evid Based Complement Alternat Med. 2020 Sep 30;2020:7603410. doi: 10.1155/2020/7603410. eCollection 2020.
8
Gut microbiota in human metabolic health and disease.人体肠道微生物群与代谢健康和疾病。
Nat Rev Microbiol. 2021 Jan;19(1):55-71. doi: 10.1038/s41579-020-0433-9. Epub 2020 Sep 4.
9
Chinese herbal medicine combined with entecavir to reduce the off-therapy recurrence risk in HBeAg-positive chronic hepatitis B patients: a multicener, double-blind, randomized controlled trial in China.中药联合恩替卡韦降低 HBeAg 阳性慢性乙型肝炎患者停药后复发风险:一项多中心、双盲、随机对照临床试验在中国。
Trials. 2020 Aug 12;21(1):708. doi: 10.1186/s13063-020-04417-9.
10
Research Progress in Chinese Medicine Preparations for Promoting Blood Circulation and Removing Blood Stasis for Cirrhotic Patients with Portal Vein Thrombosis Following Splenectomy.活血化瘀类中药制剂防治肝硬化脾切除术后门静脉血栓形成的研究进展
Chin J Integr Med. 2022 Sep;28(9):855-863. doi: 10.1007/s11655-020-3271-8. Epub 2020 Jul 20.

正肝化瘀汤联合恩替卡韦对慢性乙型肝炎肝纤维化患者肠道菌群的影响。

Effects of Zhenggan Huayu decoction combined with entecavir on gut microbiota in patients with chronic hepatitis B fibrosis.

机构信息

Department of Liver Diseases, Shenzhen Hospital, Beijing University of Chinese Medicine, Shenzhen 518172, China.

Department of Liver Diseases, Shenzhen Third People's Hospital, Guangdong 518112, China.

出版信息

J Tradit Chin Med. 2023 Jun;43(3):559-567. doi: 10.19852/j.cnki.jtcm.20230208.002.

DOI:10.19852/j.cnki.jtcm.20230208.002
PMID:37147758
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10133949/
Abstract

OBJECTIVE

To evaluate the effects of Zhenggan Huayu decoction (, ZGHY) combined with entecavir (ETV) on the gut microbiota in patients with chronic hepatitis B (CHB) fibrosis.

METHODS

A total of 59 CHB-related fibrosis patients were enrolled and treated with ZGHY combined with ETV (ZGHY + ETV) and ETV alone. Fecal samples were collected from patients at weeks 0, 12, and 24 after treatment and gut microbiota were analyzed by 16S rRNA gene sequencing.

RESULTS

Compared to the ETV group, microbiota diversity in the ZGHY + ETV group was increased after 24 weeks. Some potentially pathogenic bacteria, including spp., spp., and spp. were reduced in the ZGHY + ETV group, while spp., spp., and several other beneficial bacteria were increased.

CONCLUSION

Decreases in pathogenic bacteria and increases in probiotics were not always observed in the Traditional Chinese Medicine (TCM) group (e.g., was abundant). As an adjuvant TCM formulation for ETV, ZGHY had a positive role in the treatment of CHB patients.

摘要

目的

评价正肝化瘀汤(ZGHY)联合恩替卡韦(ETV)对慢性乙型肝炎(CHB)纤维化患者肠道微生物群的影响。

方法

共纳入 59 例 CHB 相关纤维化患者,分别采用 ZGHY 联合 ETV(ZGHY+ETV)和 ETV 单独治疗。治疗后第 0、12、24 周采集患者粪便样本,采用 16S rRNA 基因测序分析肠道微生物群。

结果

与 ETV 组相比,ZGHY+ETV 组治疗 24 周后微生物多样性增加。一些潜在的致病菌,包括 spp.、spp.和 spp.,在 ZGHY+ETV 组中减少,而 spp.、spp.和其他几种有益菌增加。

结论

中药组(如 spp. 丰富)并不总是观察到致病菌减少和益生菌增加。作为 ETV 的辅助中药配方,ZGHY 对 CHB 患者的治疗有积极作用。